Darko Cerne, Chair of the EFLM WG Distance Education and e-Learning, informs on next scheduled webinar and reminds that the free access to EFLM webinars is reserved to EFLM Academy Members (in order with the annual fee 2021)
The speaker will present a unique patented technology employing activated immune dendritic cells that specifically direct stem/progenitor cell therapeutic activity in-vitro which results in an enriched endothelial progenitor cells (EnEPCs; BGC101) product generated from a standard blood draw within a day. She will report long-term outcomes of a " first in human "pilot study of BGC101 for treating patients with severe Critical Limb Ischemia (CLI) with no available surgical option.
Stem/progenitor cell treatments with bone-marrow-derived cells show promise in treating CLI, albeit not without adverse events related to cell mobilization and collection. As of 2020, 4 years after treatment, the therapy shows promising therapeutic effects in objective outcomes including limb salvage, increased leg blood flow and wound healing, as well as in walking ability, reduction of pain, decreased usage of narcotic medications and improved quality of life.
ABOUT THE SPEAKER :
Yael Porat, PhD, is founder and CEO of BioGenCell Ltd, a biotechnology company focusing on stem cell therapy and regenerative medicine. Dr. Porat earned her PhD in immunology from the Sackler School of Medicine, TelAviv University. Prior to founding BioGenCell, she served as head of the Global Biological Development Department at Teva Pharmaceuticals (NYSE: TEVA) and as CTO at TheraVitae, where she led the translation of innovative research into the production of stem cell based therapies used to treat patients with severe cardiovascular diseases.
BioGenCell is developing groundbreaking technology for automated production of patient-specific, blood-derived stem-cell-based therapies that enable physicians to treat patients the day after diagnosis. The company’s proprietary technology utilizes immune-directed stem-cell specific activity to create cell-based products for a wide range of diseases.
European Federation of Clinical Chemistry and Laboratory Medicine
Egmontstraat 11, Brussels Belgium
You received this email because you signed up on our website or are an EFLM Academy member or an EFLM National Society's representative.